Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,309 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical and molecular characteristics of MEF2D fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including a novel translocation resulting in MEF2D-HNRNPH1 gene fusion.
Ohki K, Kiyokawa N, Saito Y, Hirabayashi S, Nakabayashi K, Ichikawa H, Momozawa Y, Okamura K, Yoshimi A, Ogata-Kawata H, Sakamoto H, Kato M, Fukushima K, Hasegawa D, Fukushima H, Imai M, Kajiwara R, Koike T, Komori I, Matsui A, Mori M, Moriwaki K, Noguchi Y, Park MJ, Ueda T, Yamamoto S, Matsuda K, Yoshida T, Matsumoto K, Hata K, Kubo M, Matsubara Y, Takahashi H, Fukushima T, Hayashi Y, Koh K, Manabe A, Ohara A; Tokyo Children’s Cancer Study Group (TCCSG). Ohki K, et al. Among authors: yamamoto s. Haematologica. 2019 Jan;104(1):128-137. doi: 10.3324/haematol.2017.186320. Epub 2018 Aug 31. Haematologica. 2019. PMID: 30171027 Free PMC article. Clinical Trial.
Residual disease detected by multidimensional flow cytometry shows prognostic significance in childhood acute myeloid leukemia with intermediate cytogenetics and negative FLT3-ITD: a report from the Tokyo Children's Cancer Study Group.
Keino D, Kinoshita A, Tomizawa D, Takahashi H, Ida K, Kurosawa H, Koike K, Ota S, Iwasaki N, Fujimura J, Yuza Y, Kiyotani C, Yamamoto S, Osumi T, Ueda T, Mochizuki S, Isoyama K, Hanada R, Tawa A, Manabe A, Toguchi Y, Ohara A. Keino D, et al. Among authors: yamamoto s. Int J Hematol. 2016 Apr;103(4):416-22. doi: 10.1007/s12185-016-1937-y. Epub 2016 Jan 18. Int J Hematol. 2016. PMID: 26781613 Clinical Trial.
Recurrent RARB Translocations in Acute Promyelocytic Leukemia Lacking RARA Translocation.
Osumi T, Tsujimoto SI, Tamura M, Uchiyama M, Nakabayashi K, Okamura K, Yoshida M, Tomizawa D, Watanabe A, Takahashi H, Hori T, Yamamoto S, Hamamoto K, Migita M, Ogata-Kawata H, Uchiyama T, Kizawa H, Ueno-Yokohata H, Shirai R, Seki M, Ohki K, Takita J, Inukai T, Ogawa S, Kitamura T, Matsumoto K, Hata K, Kiyokawa N, Goyama S, Kato M. Osumi T, et al. Among authors: yamamoto s. Cancer Res. 2018 Aug 15;78(16):4452-4458. doi: 10.1158/0008-5472.CAN-18-0840. Epub 2018 Jun 19. Cancer Res. 2018. PMID: 29921692
Prognostic value of the revised International Prognostic Scoring System five-group cytogenetic abnormality classification for the outcome prediction of hematopoietic stem cell transplantation in pediatric myelodysplastic syndrome.
Yamamoto S, Kato M, Watanabe K, Ishimaru S, Hasegawa D, Noguchi M, Hama A, Sato M, Koike T, Iwasaki F, Yagasaki H, Takahashi Y, Kosaka Y, Hashii Y, Morimoto A, Atsuta Y, Hasegawa D, Yoshida N. Yamamoto S, et al. Bone Marrow Transplant. 2021 Dec;56(12):3016-3023. doi: 10.1038/s41409-021-01446-z. Epub 2021 Sep 10. Bone Marrow Transplant. 2021. PMID: 34508178
Novel TENM3-ALK fusion is an alternate mechanism for ALK activation in neuroblastoma.
Hiwatari M, Seki M, Matsuno R, Yoshida K, Nagasawa T, Sato-Otsubo A, Yamamoto S, Kato M, Watanabe K, Sekiguchi M, Miyano S, Ogawa S, Takita J. Hiwatari M, et al. Among authors: yamamoto s. Oncogene. 2022 May;41(20):2789-2797. doi: 10.1038/s41388-022-02301-1. Epub 2022 Apr 11. Oncogene. 2022. PMID: 35411036
Postchemotherapy immune status in infants with acute lymphoblastic leukemia: A report from the JPLSG MLL-10 trial.
Arakawa Y, Hasegawa D, Miyamura T, Ohshima J, Kimura S, Imamura T, Koga Y, Yamamoto S, Ogawa A, Shinoda K, Eguchi M, Hosoi H, Imai K, Koh K, Tomizawa D. Arakawa Y, et al. Among authors: yamamoto s. Pediatr Blood Cancer. 2022 Oct;69(10):e29772. doi: 10.1002/pbc.29772. Epub 2022 Jul 7. Pediatr Blood Cancer. 2022. PMID: 35796397 Clinical Trial.
Optimizing transplantation procedures through identification of prognostic factors in second remission for children with acute myeloid leukemia with no prior history of transplant.
Ishida H, Tsujimoto SI, Hasegawa D, Sakaguchi H, Yamamoto S, Yanagimachi M, Koh K, Watanabe A, Hama A, Cho Y, Watanabe K, Noguchi M, Takeuchi M, Takita J, Washio K, Kato K, Koike T, Hashii Y, Tabuchi K, Hino M, Atsuta Y, Okamoto Y. Ishida H, et al. Among authors: yamamoto s. Haematologica. 2024 Jan 1;109(1):312-317. doi: 10.3324/haematol.2023.283203. Haematologica. 2024. PMID: 37470138 Free PMC article. No abstract available.
TBI, etoposide, and cyclophosphamide conditioning for intermediate-risk relapsed childhood acute lymphoblastic leukemia.
Ueki H, Ogawa C, Goto H, Nishi M, Yamanaka J, Mochizuki S, Nishikawa T, Kumamoto T, Nishiuchi R, Kikuta A, Yamamoto S, Igarashi S, Sato A, Hori T, Saito AM, Watanabe T, Deguchi T, Manabe A, Horibe K, Toyoda H. Ueki H, et al. Among authors: yamamoto s. Int J Hematol. 2024 Apr;119(4):450-458. doi: 10.1007/s12185-024-03710-6. Epub 2024 Jan 25. Int J Hematol. 2024. PMID: 38267673
10,309 results
You have reached the last available page of results. Please see the User Guide for more information.